Half-year report · Q2
4574.TEDINET S100WI6C
Period2025-01-01 → 2025-06-30
Filed2025-08-08
StandardJapan GAAP
ConsolidatedYes
Data checks14 of 14 passed
Key figures · 44
| Metric | Value | Period | Scope | Source row |
|---|---|---|---|---|
| Revenue | ¥2.4bn | 2025-01-01 → 2025-06-30 | Cons. | Net sales |
| Revenue | ¥6.3bn | 2024-01-01 → 2024-12-31 | Cons. | Net sales (5-year summary) |
| Revenue | ¥2.9bn | 2024-01-01 → 2024-06-30 | Cons. | Net sales |
| Operating income | ¥46m | 2025-01-01 → 2025-06-30 | Cons. | Operating income |
| Operating income | ¥482m | 2024-01-01 → 2024-06-30 | Cons. | Operating income |
| Ordinary income | ¥20m | 2025-01-01 → 2025-06-30 | Cons. | Ordinary income |
| Ordinary income | ¥688m | 2024-01-01 → 2024-12-31 | Cons. | Ordinary income loss (5-year summary) |
| Ordinary income | ¥528m | 2024-01-01 → 2024-06-30 | Cons. | Ordinary income |
| Profit before tax | ¥382m | 2025-01-01 → 2025-06-30 | Cons. | Income before income taxes |
| Profit before tax | ¥724m | 2024-01-01 → 2024-06-30 | Cons. | Income before income taxes |
| Net income (owners) | ¥279m | 2025-01-01 → 2025-06-30 | Cons. | Profit loss attributable to owners of parent |
| Net income (owners) | ¥898m | 2024-01-01 → 2024-12-31 | Cons. | Profit loss attributable to owners of parent (5-year summary) |
| Net income (owners) | ¥764m | 2024-01-01 → 2024-06-30 | Cons. | Profit loss attributable to owners of parent |
| Net income | ¥279m | 2025-01-01 → 2025-06-30 | Cons. | Profit loss |
| Net income | ¥764m | 2024-01-01 → 2024-06-30 | Cons. | Profit loss |
| Total assets | ¥11.7bn | at 2025-06-30 | Cons. | Assets |
| Total assets | ¥12.9bn | at 2024-12-31 | Cons. | Assets |
| Total assets | ¥13.4bn | at 2024-06-30 | Cons. | Total assets (5-year summary) |
| Total liabilities | ¥3.7bn | at 2025-06-30 | Cons. | Liabilities |
| Total liabilities | ¥4.9bn | at 2024-12-31 | Cons. | Liabilities |
| Net assets / equity | ¥7.9bn | at 2025-06-30 | Cons. | Net assets |
| Net assets / equity | ¥8.0bn | at 2024-12-31 | Cons. | Net assets |
| Net assets / equity | ¥8.1bn | at 2024-06-30 | Cons. | Net assets (5-year summary) |
| Cash and deposits | ¥4.1bn | at 2025-06-30 | Cons. | Cash and deposits |
| Cash and deposits | ¥4.5bn | at 2024-12-31 | Cons. | Cash and deposits |
| Cash & equivalents | ¥4.1bn | at 2025-06-30 | Cons. | Cash and cash equivalents |
| Cash & equivalents | ¥4.5bn | at 2024-12-31 | Cons. | Cash and cash equivalents |
| Cash & equivalents | ¥4.9bn | at 2024-06-30 | Cons. | Cash and cash equivalents |
| Cash & equivalents | ¥5.2bn | at 2023-12-31v | Cons. | Cash and cash equivalents |
| Operating cash flow | ¥61m | 2025-01-01 → 2025-06-30 | Cons. | Net cash provided by used in operating activities |
| Operating cash flow | ¥362m | 2024-01-01 → 2024-12-31 | Cons. | Net cash provided by used in operating activities (5-year summary) |
| Operating cash flow | ¥256m | 2024-01-01 → 2024-06-30 | Cons. | Net cash provided by used in operating activities |
| Investing cash flow | ¥295m | 2025-01-01 → 2025-06-30 | Cons. | Net cash provided by used in investment activities |
| Investing cash flow | −¥5m | 2024-01-01 → 2024-12-31 | Cons. | Net cash provided by used in investing activities (5-year summary) |
| Investing cash flow | −¥135m | 2024-01-01 → 2024-06-30 | Cons. | Net cash provided by used in investment activities |
| Financing cash flow | −¥684m | 2025-01-01 → 2025-06-30 | Cons. | Net cash provided by used in financing activities |
| Financing cash flow | −¥1.2bn | 2024-01-01 → 2024-12-31 | Cons. | Net cash provided by used in financing activities (5-year summary) |
| Financing cash flow | −¥562m | 2024-01-01 → 2024-06-30 | Cons. | Net cash provided by used in financing activities |
| EPS (basic) | ¥5.57 | 2025-01-01 → 2025-06-30 | Cons. | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥17.9 | 2024-01-01 → 2024-12-31 | Cons. | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥15.24 | 2024-01-01 → 2024-06-30 | Cons. | Basic earnings loss per share (5-year summary) |
| Equity ratio | 68.1% | at 2025-06-30 | Cons. | Equity to asset ratio (5-year summary) |
| Equity ratio | 61.7% | at 2024-12-31 | Cons. | Equity to asset ratio (5-year summary) |
| Equity ratio | 60.3% | at 2024-06-30 | Cons. | Equity to asset ratio (5-year summary) |
Periods use the dates stated in the filing. d = earlier-year period dated by calendar; v = that date confirmed by the company's own earlier filing.
Segments · 26
| Segment | Item | Period | Value |
|---|---|---|---|
| Otherother segments | revenue | 2025-01-01 → 2025-06-30 | ¥2m |
| Otherother segments | revenue external | 2025-01-01 → 2025-06-30 | ¥2m |
| Otherother segments | segment profit | 2025-01-01 → 2025-06-30 | −¥7m |
| Reconciling Itemsreconciling | segment profit | 2025-01-01 → 2025-06-30 | −¥396m |
| jpcrp040300-q2r_E22560-000Infection Control Businessreportable segment | revenue | 2025-01-01 → 2025-06-30 | ¥203m |
| jpcrp040300-q2r_E22560-000Infection Control Businessreportable segment | revenue external | 2025-01-01 → 2025-06-30 | ¥203m |
| jpcrp040300-q2r_E22560-000Infection Control Businessreportable segment | segment profit | 2025-01-01 → 2025-06-30 | −¥151m |
| jpcrp040300-q2r_E22560-000Pharmaceuticals Businessreportable segment | revenue | 2025-01-01 → 2025-06-30 | ¥2.2bn |
| jpcrp040300-q2r_E22560-000Pharmaceuticals Businessreportable segment | revenue external | 2025-01-01 → 2025-06-30 | ¥2.2bn |
| jpcrp040300-q2r_E22560-000Pharmaceuticals Businessreportable segment | segment profit | 2025-01-01 → 2025-06-30 | ¥601m |
| Total Of Reportable Segments And Otherssegment total | revenue | 2025-01-01 → 2025-06-30 | ¥2.4bn |
| Total Of Reportable Segments And Otherssegment total | revenue external | 2025-01-01 → 2025-06-30 | ¥2.4bn |
| Total Of Reportable Segments And Otherssegment total | segment profit | 2025-01-01 → 2025-06-30 | ¥443m |
| Otherother segments | revenue | 2024-01-01 → 2024-06-30 | ¥2m |
| Otherother segments | revenue external | 2024-01-01 → 2024-06-30 | ¥2m |
| Otherother segments | segment profit | 2024-01-01 → 2024-06-30 | −¥6m |
| Reconciling Itemsreconciling | segment profit | 2024-01-01 → 2024-06-30 | −¥401m |
| jpcrp040300-q2r_E22560-000Infection Control Businessreportable segment | revenue | 2024-01-01 → 2024-06-30 | ¥203m |
| jpcrp040300-q2r_E22560-000Infection Control Businessreportable segment | revenue external | 2024-01-01 → 2024-06-30 | ¥203m |
| jpcrp040300-q2r_E22560-000Infection Control Businessreportable segment | segment profit | 2024-01-01 → 2024-06-30 | −¥195m |
| jpcrp040300-q2r_E22560-000Pharmaceuticals Businessreportable segment | revenue | 2024-01-01 → 2024-06-30 | ¥2.7bn |
| jpcrp040300-q2r_E22560-000Pharmaceuticals Businessreportable segment | revenue external | 2024-01-01 → 2024-06-30 | ¥2.7bn |
| jpcrp040300-q2r_E22560-000Pharmaceuticals Businessreportable segment | segment profit | 2024-01-01 → 2024-06-30 | ¥1.1bn |
| Total Of Reportable Segments And Otherssegment total | revenue | 2024-01-01 → 2024-06-30 | ¥2.9bn |
| Total Of Reportable Segments And Otherssegment total | revenue external | 2024-01-01 → 2024-06-30 | ¥2.9bn |
| Total Of Reportable Segments And Otherssegment total | segment profit | 2024-01-01 → 2024-06-30 | ¥884m |
Segment names come from EDINET member IDs; not yet mapped to a common taxonomy.
All source rows · 523
| Item | Context | Value | Unit |
|---|---|---|---|
| Net sales | CurrentYTDDuration_OtherReportableSegmentsMember | 2000000 | JPY |
| Net sales | CurrentYTDDuration_TotalOfReportableSegmentsAndOthersMember | 2412000000 | JPY |
| Net sales | CurrentYTDDuration_ReconcilingItemsMember | － | JPY |
| Net sales | CurrentYTDDuration | 2412000000 | JPY |
| Operating income | CurrentYTDDuration_jpcrp040300-q2r_E22560-000PharmaceuticalsBusinessReportableSegmentsMember | 601000000 | JPY |
| Operating income | CurrentYTDDuration_jpcrp040300-q2r_E22560-000InfectionControlBusinessReportableSegmentsMember | -151000000 | JPY |
| Operating income | CurrentYTDDuration_OtherReportableSegmentsMember | -7000000 | JPY |
| Operating income | CurrentYTDDuration_TotalOfReportableSegmentsAndOthersMember | 443000000 | JPY |
| Operating income | CurrentYTDDuration_ReconcilingItemsMember | -396000000 | JPY |
| Operating income | CurrentYTDDuration | 46000000 | JPY |
| Document title cover page | FilingDateInstant | Original text (Japanese)半期報告書 | |
| Clause of stipulation cover page | FilingDateInstant | Original text (Japanese)金融商品取引法第24条の５第１項の表の第１号 | |
| Place of filing cover page | FilingDateInstant | Original text (Japanese)近畿財務局長 | |
| Filing date cover page | FilingDateInstant | 2025-08-08 | |
| Quarterly accounting period cover page | FilingDateInstant | Original text (Japanese)第80期中（自 2025年１月１日 至 2025年６月30日） | |
| Company name cover page | FilingDateInstant | Original text (Japanese)大幸薬品株式会社 | |
| Company name in english cover page | FilingDateInstant | TAIKO PHARMACEUTICAL CO.,LTD. | |
| Title and name of representative cover page | FilingDateInstant | Original text (Japanese)代表取締役社長 柴田 高 | |
| Address of registered headquarter cover page | FilingDateInstant | Original text (Japanese)大阪府吹田市内本町三丁目34番14号（同所は登記上の本店所在地で実際の業務は「最寄りの連絡場所」で行っております。） | |
| Telephone number address of registered headquarter cover page | FilingDateInstant | Original text (Japanese)該当事項はありません。 | |
| Name of contact person address of registered headquarter cover page | FilingDateInstant | Original text (Japanese)該当事項はありません。 | |
| Nearest place of contact cover page | FilingDateInstant | Original text (Japanese)大阪府大阪市西区西本町一丁目４番１号 オリックス本町ビル16階 | |
| Telephone number nearest place of contact cover page | FilingDateInstant | Original text (Japanese)０６－４３９１－１１１０（代表） | |
| Name of contact person nearest place of contact cover page | FilingDateInstant | Original text (Japanese)コーポレート本部 経理部長 中條 亨 | |
| Place for public inspection cover page (text) | FilingDateInstant | Text · Plus | |
| Edinet code | FilingDateInstant | E22560 | |
| Fund code | FilingDateInstant | － | |
| Security code | FilingDateInstant | 45740 | |
| Filer name in japanese | FilingDateInstant | Original text (Japanese)大幸薬品株式会社 | |
| Filer name in english | FilingDateInstant | TAIKO PHARMACEUTICAL CO.,LTD. | |
| Fund name in japanese | FilingDateInstant | － | |
| Fund name in english | FilingDateInstant | － | |
| Cabinet office ordinance | FilingDateInstant | Original text (Japanese)企業内容等の開示に関する内閣府令 | |
| Document type | FilingDateInstant | Original text (Japanese)第四号の三様式 | |
| Accounting standards | FilingDateInstant | Japan GAAP | |
| Whether consolidated financial statements are prepared | FilingDateInstant | true | |
| Industry code when consolidated financial statements are prepared in accordance with industry specific regulations | FilingDateInstant | CTE | |
| Industry code when financial statements are prepared in accordance with industry specific regulations | FilingDateInstant | － | |
| Current fiscal year start date | FilingDateInstant | 2025-01-01 | |
| Current period end date | FilingDateInstant | 2025-06-30 | |
| Type of current period | FilingDateInstant | Q2 | |
| Current fiscal year end date | FilingDateInstant | 2025-12-31 | |
| Previous fiscal year start date | FilingDateInstant | 2024-01-01 | |
| Comparative period end date | FilingDateInstant | 2024-06-30 | |
| Previous fiscal year end date | FilingDateInstant | 2024-12-31 | |
| Next fiscal year start date | FilingDateInstant | － | |
| End date of quarterly or semi annual period of next fiscal year | FilingDateInstant | － | |
| Amendment flag | FilingDateInstant | false | |
| Identification of document subject to amendment | FilingDateInstant | － | |
| Report amendment flag | FilingDateInstant | false |
Every row of the EDINET CSV. Item names are the XBRL element names; filed text is kept in its original Japanese. Filed text is available on Plus and Pro.
Data checks · 14 of 14 passed
| balance sheet identity | pass rounding |
| balance sheet identity | pass rounding |
| dei present | pass |
| period resolution | pass |
| statement vs summary · net assets | pass |
| statement vs summary · net assets | pass |
| statement vs summary · net income attributable to parent | pass |
| statement vs summary · net income attributable to parent | pass |
| statement vs summary · operating cash flow | pass |
| statement vs summary · operating cash flow | pass |
| statement vs summary · revenue | pass |
| statement vs summary · revenue | pass |
| statement vs summary · total assets | pass |
| statement vs summary · total assets | pass |